Article
A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors.
Cell reports - 15 Mar 2022
Fernández-Pisonero Isabel, Clavaín Laura, Robles-Valero Javier, Lorenzo-Martín L Francisco, Caloto Rubén, Nieto Blanca, García-Macías Carmen, Oeste Clara L, Sánchez-Martín Manuel, Abad Antonio, Hortal Alejandro, Caballero Dolores, González Marcos, Dosil Mercedes, Alarcón Balbino, Bustelo Xosé R
Abstract excerpt
A missense change in RRAS2 (Gln72 to Leu), analogous to the Gln61-to-Leu mutation of RAS oncoproteins, has been identified as a long-tail hotspot mutation in cancer and Noonan syndrome. However, the relevance of this mutation for in vivo tumorigenesis remains understudied. Here we show, using an inducible knockin mouse model, that R-Ras2Q72L triggers rapid development of a wide spectrum of tumors when somatically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.